Goldman initiated coverage on Abbott Labs with a new price target
$ABT
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $121.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $130.00 | Outperform | Oppenheimer |
| 9/19/2024 | $131.00 | Overweight | Piper Sandler |
| 7/30/2024 | Buy → Hold | Edward Jones | |
| 5/30/2024 | $121.00 | Buy | Goldman |
| 7/21/2023 | Underperform → Peer Perform | Wolfe Research | |
| 5/30/2023 | $112.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/20/2023 | $125.00 → $127.00 | Overweight | Barclays |
| 4/20/2023 | $107.00 → $103.00 | Underperform | Wolfe Research |
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
Canadians living with type 2 diabetes agree that uplifting words, positive feedback and supportive tools are the most powerful motivatorsMISSISSAUGA, ON, Oct. 30, 2024 /CNW/ -- Abbott (NYSE:ABT) today released new data highlighting the emotional challenges faced by people living with type 2 diabetes, revealing key motivators to help them manage their condition. Nearly 12 million Canadians are living with diabetes or pre-diabetes, and the overwhelming majority have or will be diagnosed with type 2.1 While a variety of factors contribute to the risk of developing type 2 diabetes
Tidepool partners with Abbott for seamless data integration, expanding patient choice, and streamlining diabetes care workflows. Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration partnership with continuous glucose monitoring (CGM) manufacturer Abbott (NYSE:ABT). A major development towards the goal of patient and provider choice, the cloud-to-cloud integration will provide a continuous, automatic stream of data from patients using FreeStyle Libre CGM to Tidepool+. Tidepool+, a diabetes data visualization and population health platform, provides intuitive tracking and visualization of diabetes data making the data
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failureTrial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progressionABBOTT PARK, Ill., Oct. 24, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial, which is planned to enroll up to 850 patients across 75 sites worldwide, will measure pulmonary artery pressures (PAP) using
Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00
Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00
Edward Jones downgraded Abbott Labs from Buy to Hold
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics. Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits. Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage. Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month. Abbott’s consumer bi
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the “Neutral” zone on Thursday. U.S. stocks closed lower on Thursday, with the Dow Jones index falling more than 500 points during the session. On the economic data front, U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000. The Philadelphia Fed Manufacturing Index rose to 13.9 in July, recording the strongest level in three months, versus 1.3 in June. Abbott Laboratories (NYSE:ABT) reported better-than-expected earnings for its second quarter on Thursday. D.R. Horton, Inc. (NYSE:DHI) reported stronge
Shares of Abbott Laboratories (NYSE:ABT) are trading lower on Thursday following the company’s second-quarter 2024 financial results. What’s Going On: Abbott reported second-quarter sales of $10.377 billion, slightly beating the $10.371 billion estimate. EPS came in at $1.14, surpassing analyst estimates of $1.10. The company also saw a 10.2% increase in sales to $4.73 billion and a 12.1% organic growth rate. This growth included double-digit gains in Diabetes Care, Electrophysiology and Structural Heart sectors. Despite the growth in medical devices, diagnostics sales were impacted by a year-over-year decline in COVID-19 testing-related sales, which dropped to $102 million from $26
Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical dataABBOTT PARK, Ill., Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2024. Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items.Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding
ABBOTT PARK, Ill., Sept. 25, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2024 financial results on Wednesday, Oct. 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medic
ABBOTT PARK, Ill., Sept. 19, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 403rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2024, to shareholders of record at the close of business on Oct. 15, 2024. Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfoli
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime
PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors. "I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystal's evolution," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. "As a seasoned executive with extensive valuable pharmaceutical and biotechnology industry experience, I look forward to Catherine's involvement and assistance in guiding our strategic objectives." "A
Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer. Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories (NYSE:ABT). During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice P
LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D